Teva Pharmaceutical - best Pharma Stocks of 2007
Company: Teva Pharmaceutical
Starting stock price: $31.26
Ending stock price: $46.48
Percent Change: 48.69%
Details: Generic drug powerhouse Teva Pharmaceuticals had a great year in 2007. The company received FDA approval for 28 new products, including generic versions of Aricept, Requip, Actonel, Coreg, and Protonix. Teva's revenue rose 12 percent year over 2006, which was another blockbuster year for the drugmaker. And with more blockbuster drugs on their way to generics land, things can only get better for Teva.
More News:
Teva snaps up CoGenesys in $400M buyout. Report
Teva earmarks $1B for India. Report
Earnings from Schering, Sanofi, Teva. Report
Analysts get bullish on generics makers. Report
More stories about Teva Pharmaceutical
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: